What do you talk about around the Thanksgiving table or while watching the 100th Macy's Thanksgiving Day Parade?
PBM acquisitions? Drug negotiation? Part D premiums?
...none of those? Well...at least you can still talk to us.
In this issue: Extra: A Cheat Sheet for Medicare Part D Terms
P.S. Join my nearly 47,000 LinkedIn followers for more analysis of pharmacy economics and drug channel news. Or just to talk pharmacy because your family doesn't understand.
Are you ready for what's coming next year?
Join the upcoming live video webinar Drug Channels Outlook 2027 on December 11, 2026, from 12:00 p.m. to 1:30 p.m. ET. More details here. There are special discounts if you want to bring your whole team!
MedImpact's Proposed Acquisition of VytlOne's PBM and Gateway Health Partners, Bryce Platt on LinkedIn
The PBM shakeout continues.
Drug Channels Institute learned that MedImpact had agreed to acquire VytlOne's PBM business and its affiliate, Gateway Health Partners. The proposed transaction excludes VytlOne's 340B and pharmacy fulfillment assets.
The chart below places VytlOne within the broader landscape of smaller PBMs and the shakeout already underway.
Smaller PBMs face a difficult combination of rising compliance demands, reliance on larger organizations for parts of their operations, and competition over how best to demonstrate value to plan sponsors. Recent federal requirements and a patchwork of state laws add to the resources needed to operate.
Scale can help spread those costs, but consolidation may also leave plan sponsors with fewer independent options. As Adam Fein explained in this PBM shakeout video, the important question for customers is whether a PBM can deliver competitive costs and reliable service—not just promise transparency.
Drug Channels Institute learned that MedImpact had agreed to acquire VytlOne's PBM business and its affiliate, Gateway Health Partners. The proposed transaction excludes VytlOne's 340B and pharmacy fulfillment assets.
The chart below places VytlOne within the broader landscape of smaller PBMs and the shakeout already underway.
[Click to Enlarge]
Smaller PBMs face a difficult combination of rising compliance demands, reliance on larger organizations for parts of their operations, and competition over how best to demonstrate value to plan sponsors. Recent federal requirements and a patchwork of state laws add to the resources needed to operate.
Scale can help spread those costs, but consolidation may also leave plan sponsors with fewer independent options. As Adam Fein explained in this PBM shakeout video, the important question for customers is whether a PBM can deliver competitive costs and reliable service—not just promise transparency.
Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Final Rule (CMS-4215-F), Centers for Medicare & Medicaid Services
CMS has finalized rules for the next phase of Medicare drug price negotiation, covering initial price applicability year 2029 and beyond. The final rule is a long one (695 pages) including the selection and negotiation process, a temporary price floor for certain small biotech drugs, and rules for generic and biosimilar competition and Part D coverage.
Side note: this final rule didn't include anything for MFP effectuation of Part B drugs.
One provision addresses how CMS will identify a potential qualifying single source drug when a new formulation adds an ingredient that enables a different route of administration. Under the policy, certain products with the same application holder and a shared active ingredient can be grouped together for negotiation purposes.
The visual below summarizes the potential benefits and drawbacks of applying negotiated prices across qualifying formulations.
Not every reformulation delivers the same clinical value. The challenge is that a policy designed to address spending can also change the incentives for improvements that matter to patients.
Side note: this final rule didn't include anything for MFP effectuation of Part B drugs.
One provision addresses how CMS will identify a potential qualifying single source drug when a new formulation adds an ingredient that enables a different route of administration. Under the policy, certain products with the same application holder and a shared active ingredient can be grouped together for negotiation purposes.
The visual below summarizes the potential benefits and drawbacks of applying negotiated prices across qualifying formulations.
[Click to Enlarge]
Not every reformulation delivers the same clinical value. The challenge is that a policy designed to address spending can also change the incentives for improvements that matter to patients.
Medicare Part D Premiums and Cost Sharing in 2027, KFF
What will happen to premiums for stand-alone Medicare Part D prescription drug plans (PDPs) in 2027? It depends who you ask.
KFF projects that the average monthly PDP premium will rise from $34 in 2026 to $51 in 2027—a 50% increase—if current enrollees remain in their existing plans. By contrast, CMS projected an increase of less than $1, from $35.09 to $36.
Here's a comparison of the projections and what KFF found for current PDP enrollees.
KFF notes that switching to lower-premium plans is one possible reason for the difference, but CMS's assumptions are not clear, so it's hard to tell. The actual 2027 average will likely end up lower than KFF's $51 estimate once switching and new enrollment are taken into account, but very unlikely to be $36.
Premiums are only part of the decision. KFF also estimates that the average PDP deductible will rise from $540 to $643. A less expensive plan may have different drug coverage, cost sharing, or pharmacy networks, so beneficiaries should review those details before choosing.
Unfortunately, they'll have less plans to choose from after more than 4 million Medicare beneficiaries have their MAPD or PDP plan terminated at the end of 2026, continuing the decline of PDPs we have covered for years as a result of the IRA.
KFF projects that the average monthly PDP premium will rise from $34 in 2026 to $51 in 2027—a 50% increase—if current enrollees remain in their existing plans. By contrast, CMS projected an increase of less than $1, from $35.09 to $36.
Here's a comparison of the projections and what KFF found for current PDP enrollees.
[Click to Enlarge]
KFF notes that switching to lower-premium plans is one possible reason for the difference, but CMS's assumptions are not clear, so it's hard to tell. The actual 2027 average will likely end up lower than KFF's $51 estimate once switching and new enrollment are taken into account, but very unlikely to be $36.
Premiums are only part of the decision. KFF also estimates that the average PDP deductible will rise from $540 to $643. A less expensive plan may have different drug coverage, cost sharing, or pharmacy networks, so beneficiaries should review those details before choosing.
Unfortunately, they'll have less plans to choose from after more than 4 million Medicare beneficiaries have their MAPD or PDP plan terminated at the end of 2026, continuing the decline of PDPs we have covered for years as a result of the IRA.
Regression-based analysis of Medicare hospital outpatient drug spend at 340B participating hospitals, Milliman
A PhRMA-commissioned Milliman study gives us a more rigorous comparison of Medicare Part B fee-for-service outpatient drug spending at 340B and non-340B hospitals from 2019 through 2024. The researchers used patient and hospital characteristics to match drug utilizers and repriced affected claims to a consistent average sales price plus 6% (ASP+6%).
Across the study years, monthly spending per drug utilizer at 340B hospitals was 20% to 52% higher than at the matched non-340B hospitals. The researchers identified both more drug claims per utilizer and higher allowed spending per claim in the 340B hospital group.
The chart below breaks out those two contributors by year.
There are also some interesting data cuts in the appendices if you want to see how the 340B hospitals compare in other aspects:
Across the study years, monthly spending per drug utilizer at 340B hospitals was 20% to 52% higher than at the matched non-340B hospitals. The researchers identified both more drug claims per utilizer and higher allowed spending per claim in the 340B hospital group.
The chart below breaks out those two contributors by year.
[Click to Enlarge]
There are also some interesting data cuts in the appendices if you want to see how the 340B hospitals compare in other aspects:
- Patient age, gender, and race
- Medicare eligibility and dual eligibility status
- Hospice and long-term institutional status
- Disease group
- Hospital teaching status, bed count, and urban or rural location
- Years of hospital participation in the 340B program
Master Medicare Part D Terms for the Annual Enrollment Period, Bryce Platt on LinkedIn
Medicare's annual enrollment period brings with it a challenge of understanding the many terms that describe what a Part D plan covers and what its members pay.
I put together the reference below to help interpret the language of Part D. Feel free to message me on LinkedIn or email if you'd like a high-resolution PDF version.
I put together the reference below to help interpret the language of Part D. Feel free to message me on LinkedIn or email if you'd like a high-resolution PDF version.
[Click to Enlarge]





